Dyspareunia

Postmenopausal women with vulvovaginal atrophy treated with intravaginal prasterone for at least 12 weeks were nearly 50% less likely to develop a urinary tract infection compared with untreated women, researchers reported in Menopause.

Vaginal estrogen, vaginal dehydroepiandrosterone, oral ospemifene and vaginal moisturizers result in short-term improvements in vaginal atrophy symptoms, known as genitourinary syndrome of menopause, but more long-term data are needed.

Relugolix combination therapy may be an effective and safe long-term treatment option for premenopausal women with endometriosis and nonmenstrual pelvic pain, researchers reported in Human Reproduction.

Postmenopausal women assigned daily oral lasofoxifene had significant and clinically meaningful improvements in vulvovaginal atrophy symptoms with a favorable safety profile, researchers reported in Menopause.

Testosterone use among transgender men and gender-diverse people was linked to higher interest in sexual activity and also pain or discomfort during sexual activity, researchers reported.

BALTIMORE — Repeated use of water-based lubricants did not appear to significantly alter the vaginal microbiome of premenopausal and postmenopausal women for up to 4 weeks after application, researchers reported.

Estradiol cream applied to the vulvar vestibule plus precoital silicone lubricant may offer an alternative to vaginal therapy for women with dyspareunia, according to a randomized pilot trial published in Menopause.

Adolescents seeking an abortion demonstrated comparable accuracy in estimating gestational duration as older age groups, according to a research letter published in JAMA Pediatrics.